Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Leukemia ; 30(4): 929-36, 2016 Apr.
Article in English | MEDLINE | ID: mdl-26639181

ABSTRACT

In chronic lymphocytic leukemia (CLL) the level of minimal residual disease (MRD) after therapy is an independent predictor of outcome. Given the increasing number of new agents being explored for CLL therapy, using MRD as a surrogate could greatly reduce the time necessary to assess their efficacy. In this European Research Initiative on CLL (ERIC) project we have identified and validated a flow-cytometric approach to reliably quantitate CLL cells to the level of 0.0010% (10(-5)). The assay comprises a core panel of six markers (i.e. CD19, CD20, CD5, CD43, CD79b and CD81) with a component specification independent of instrument and reagents, which can be locally re-validated using normal peripheral blood. This method is directly comparable to previous ERIC-designed assays and also provides a backbone for investigation of new markers. A parallel analysis of high-throughput sequencing using the ClonoSEQ assay showed good concordance with flow cytometry results at the 0.010% (10(-4)) level, the MRD threshold defined in the 2008 International Workshop on CLL guidelines, but it also provides good linearity to a detection limit of 1 in a million (10(-6)). The combination of both technologies would permit a highly sensitive approach to MRD detection while providing a reproducible and broadly accessible method to quantify residual disease and optimize treatment in CLL.


Subject(s)
Antigens, CD/metabolism , Flow Cytometry/standards , High-Throughput Nucleotide Sequencing/methods , Leukemia, Lymphocytic, Chronic, B-Cell/therapy , Neoplasm, Residual/diagnosis , Adolescent , Adult , Combined Modality Therapy , Europe , Female , Follow-Up Studies , Humans , Immunophenotyping , Leukemia, Lymphocytic, Chronic, B-Cell/pathology , Male , Neoplasm Staging , Neoplasm, Residual/genetics , Neoplasm, Residual/metabolism , Prognosis , Young Adult
2.
Leukemia ; 27(1): 142-9, 2013 Jan.
Article in English | MEDLINE | ID: mdl-23041722

ABSTRACT

Detection of minimal residual disease (MRD) in chronic lymphocytic leukaemia (CLL) is becoming increasingly important as treatments improve. An internationally harmonised four-colour (CLR) flow cytometry MRD assay is widely used but has limitations. The aim of this study was to improve MRD analysis by identifying situations where a less time-consuming CD19/CD5/κ/λ analysis would be sufficient for detecting residual CLL, and develop a six-CLR antibody panel that is more efficient for cases requiring full MRD analysis. In 784 samples from CLL patients after treatment, it was possible to determine CD19/CD5/κ/λ thresholds that identified cases with detectable MRD with 100% positive predictive value (PPV). However, CD19/CD5/κ/λ analysis was unsuitable for predicting iwCLL/NCI response status or identifying cases with no detectable MRD. For the latter cases requiring a full MRD assessment, a six-CLR assay was designed comprising CD19/CD5/CD20 with (1) CD3/CD38/CD79b and (2) CD81/CD22/CD43. There was good correlation between four-CLR and six-CLR panels in dilution studies and clinical samples, with 100% concordance for detection of residual disease at the 0.01% (10(-4)) level (n=59) and good linearity even at the 0.001-0.01% (10(-5)-10(-4)) level. A six-CLR panel therefore provides equivalent results to the four-CLR panel but it requires fewer reagents, fewer cells and a much simpler analysis approach.


Subject(s)
Biomarkers, Tumor/analysis , Flow Cytometry/standards , Leukemia, Lymphocytic, Chronic, B-Cell/pathology , Neoplasm, Residual/diagnosis , Antigens, CD/analysis , Europe , Humans , Immunoglobulin Light Chains/immunology , Immunoglobulin kappa-Chains/immunology , Immunoglobulin lambda-Chains/immunology , Immunophenotyping , Leukemia, Lymphocytic, Chronic, B-Cell/immunology , Neoplasm Staging , Neoplasm, Residual/immunology , Prognosis , Sensitivity and Specificity
3.
Clin Lymphoma Myeloma Leuk ; 11(1): 176-9, 2011 Feb.
Article in English | MEDLINE | ID: mdl-21856554

ABSTRACT

Histological transformation, typically to diffuse large B-cell lymphoma (DLBCL) is reported to occur in 5%-10% of patients with WM and recent studies have highlighted a possible aetiological role for the nucleoside analogues. It is however becoming increasingly clear that histological transformation is a complex phenomenon and may include clonally unrelated disorders. In order to highlight this pathological heterogeneity we describe 5 patients with diverse histological progression events. These included EBV-associated events namely DLBCL, peripheral T-cell lymphoma and spontaneously resolving mucocutaneous ulcer. A further 2 patients demonstrated a localised plasma cell rich lesion simulating plasmacytoma and a de novo DLBCL arising in an unrelated B-cell clone. It is clear therefore that detailed pathological assessments are required in all suspected cases of transformation and that the pathological heterogeneity demonstrated by this study needs to be taken into account when potential aetiological factors are being assessed.


Subject(s)
Lymphoma, Large B-Cell, Diffuse/pathology , Lymphoma, T-Cell, Peripheral/pathology , Waldenstrom Macroglobulinemia/pathology , Aged , Aged, 80 and over , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Fatal Outcome , Female , Humans , Lymphoma, Large B-Cell, Diffuse/drug therapy , Lymphoma, Large B-Cell, Diffuse/etiology , Lymphoma, T-Cell, Peripheral/drug therapy , Lymphoma, T-Cell, Peripheral/etiology , Male , Middle Aged , Treatment Outcome , Waldenstrom Macroglobulinemia/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...